PPARG and diabetes mellitus: Rats with diabetes initiated by STZ were subjected to hesperidin treatment (100 mg/kg orally), the antagonist of PPAR-γ GW9662 (1 mg/kg intraperitoneal injection), or a mix of both compounds.